Pfizer Inc
Why Medicare price negotiations matter for Novo Nordisk, AstraZeneca, and other European pharma companies
Drug pricing has emerged as a key topic to watch for pharmaceutical companies and investors in 2025. As President Donald Trump pushes for lower medicine prices for Americans, the sector is facing additional pricing pressure from a Biden-era law called the Inflation Reduction Act. The IRA, voted into law in 2022, allows the Centers for […]
Read More
Novo Nordisk’s leadership strategy tested as shareholders signal frustration ahead of vote on board revamp
Flags with the logos of Danish drugmaker Novo Nordisk, maker of the blockbuster diabetes and weight-loss treatments Ozempic and Wegovy are pictures while the company presents the annual report at Novo Nordisk in Bagsvaerd, Denmark, on February 5, 2025. Mads Claus Rasmussen | Afp | Getty Images A leadership shakeup at what was once Europe’s […]
Read More
Stocks making the biggest moves midday: Walt Disney, Sweetgreen, Cisco, Planet Fitness and more
Check out the companies making headlines in midday trading: Planet Fitness — The gym chain jumped about 4% after it issued guidance for the fiscal years 2026 through 2028. Planet Fitness expects new club unit growth to range between 6% and 7% in that time, while adjusted EBITA expands in the “mid-teens percent” compounded annually. […]
Read More
Healthy Returns: Novo Nordisk boosts the case for its upcoming obesity pill with additional data
A view shows a Novo Nordisk sign outside its office in Bagsvaerd, on the outskirts of Copenhagen, Denmark, on July 14, 2025. Tom Little | Reuters A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. All […]
Read More
Novo Nordisk walked away from a $10 billion biotech deal — and investors aren’t sure if that’s smart or scary
Novo Nordisk has a lot on its plate — and it may not all be healthy. The pharmaceutical giant pulled out of its bidding war against rival Pfizer for clinical-stage biotech Metsera when the U.S. juggernaut matched its latest offer. Metsera accepted Pfizer’s $10 billion deal — significantly more than what Pfizer had initially offered […]
Read More
Metsera accepts Pfizer’s $10 billion bid in ongoing M&A battle
Smith Collection | Archive Photos | Getty Images Obesity drug developer Metsera said on Friday that it had accepted Pfizer‘s $10 billion acquisition offer, in what could spell the end of a bidding war between the New York-based pharma giant and rival Novo Nordisk that erupted over the last week. Pfizer had appeared to have […]
Read More
Trump announces deals with Eli Lilly, Novo Nordisk to slash weight loss drug prices, offer some Medicare coverage
U.S. President Donald Trump attends an event to make an announcement from the Oval Office at the White House in Washington, D.C., U.S. Nov. 6, 2025. Jonathan Ernst | Reuters President Donald Trump on Thursday announced deals with Eli Lilly and Novo Nordisk to slash the prices of some of their obesity drugs, including upcoming […]
Read More
Eli Lilly to start late-stage trials on amylin obesity drug after it shows up to 20% weight loss in study
Eli Lilly Biotechnology Center is shown in San Diego, California, March 1, 2023. Mike Blake | Reuters Eli Lilly on Thursday said it will start late-stage trials on its experimental amylin obesity drug next month after it showed encouraging results in a mid-stage study. The highest dose of the weekly injection, called eloralintide, helped patients […]
Read More
Healthy Returns: What to know about Pfizer and Novo Nordisk’s bidding war over obesity biotech Metsera
A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Pfizer and Novo Nordisk are in a takeover clash over the obesity biotech Metsera, with both pharmaceutical giants raising their bids for the startup as of Monday. […]
Read More
Ozempic maker Novo Nordisk lowers growth outlook for its weight loss drugs as pricing pressures mount
A box of Ozempic sits on a table in North Tyneside, Britain, Oct. 31, 2023. Lee Smith | Reuters Danish pharmaceutical giant Novo Nordisk said Wednesday it is trimming its growth expectations for its leading obesity and diabetes treatments as competition intensifies and pricing pressures mount in the weight loss market. Net profit for the […]
Read More